Table 2: Treatment Outcomes in the Intention-to-Treat Population.
Outcome | All, n = 50 | SOF/LDV, n = 31 | SOF/VEL, n = 7 | EBR/GZR, n = 8 | OBV/PTV/r + DSV +/- RBV, n = 4 |
SVR12 | 42 (84) | 26 (84) | 6 (86) | 6 (75) | 4 (100) |
SVR12 according to GT | |||||
GT1 | 36/43 (84) | 25/30 (83) | 1/1 (100) | 6/8 (75) | 4/4 (100) |
GT1a | 26/30 (87) | 17/21 (81) | - | 7/7 (100) | 2/2 (100) |
GT1b | 11/13 (85) | 8/9 (89) | 1/1 (100) | 0/1 (0) | 2/2 (100) |
GT2 | 3/3 (100) | - | 3/3 (100) | - | - |
GT3 | 2/3 (67) | - | 2/3 (67) | - | - |
GT4 | 1/1 (100) | 1/1 (100) | - | - | - |
SVR12 according to liver fibrosis status | |||||
F0-F2 | 18/22 (82) | 12/14 (86) | 3/4 (75) | 2/3 (67) | 1/1 (100) |
F3-F4 | 24/28 (86) | 14/17 (82) | 3/3 (100) | 4/5 (80) | 3/3 (100) |
Virologic failure | |||||
On-treatment failure | 1 (2)* | 1 (3)* | |||
Post-treatment relapse | 3 (6) | 2 (6) | 1 (14) | 0 | 0 |
Failure due to other reasons | |||||
LTFU after EOT | 3 (6) | 2 (6) | 0 | 1 (13) | 0 |
Death | 2 (4)* | 1 (3)* | 0 | 1 (13) | 0 |
DSV: Dasabuvir; EBR/GZR: Elbasvir/grazoprevir; EOT: End of treatment; F0-F2: Fibrosis stage 0 to 2; F3-F4: Fibrosis stage 3 (advanced fibrosis) to 4 (cirrhosis); GT: Genotype; OBV/PTV/r: Ombitasvir/paritaprevir/ritonavir; LTFU: Lost to follow up; RBV: Ribavirin; SOF/LDV: Sofosbuvir/ledipasvir; SOF/VEL: Sof osbuvir/velpatasvir.
*One patient is counted twice; this patient experienced on-treatment failure and died.